Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
RALEIGH, N.C, May 04, 2017 -- It is a little known fact that 70% of medicines given to children have been studied only in adults. As a result, most drugs used to treat diseases in children are used off-label. While there are pediatric clinical trial regulations in place, testing drugs in children continues to present considerable scientific, clinical, ethical and logistical challenges. In an effort to confront these challenges, PRA Health Sciences (NASDAQ:PRAH) is pleased to announce its new Center for Pediatric Clinical Development.
“PRA has a strong background in conducting pediatric clinical trials,” said Mark Sorrentino, Vice President, The Center for Pediatric Clinical Development. “We see this new center as an opportunity to establish PRA as the industry leader in pediatric drug development and bring innovation to pediatric clinical trial design and implementation.”
PRA has conducted the pivotal and/or supportive trials to gain 12 FDA and/or international regulatory approvals for drugs used in treating pediatric patients across multiple therapeutic areas. The Center for Pediatric Clinical Development is supported by a cross-functional group of experts who will provide strategic pediatric product development consulting services as well as experienced technical and operational services.
“This pediatric collaboration team provides the foundation for The Center for Pediatric Clinical Development,” added Sorrentino. “The team will provide pediatric expertise across functional areas into a single global resource to support all aspects of our clients’ pediatric product development needs.”
The team will help navigate the complexities of pediatric trials and brings a wealth of knowledge in understanding the diverse country-specific regulatory and legal challenges in the pediatric environment. One of the many benefits of the center will be a site network to accelerate patient recruitment, and improve patient engagement and retention.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and over 13,000 employees worldwide. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit www.prahs.com.
INQUIRIES: Christine Rogers, Manager – Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +1 919.786.8463
